Celgene Corp. (NASDAQ:CELG)‘s stock had its “outperform” rating reissued by equities research analysts at BMO Capital Markets in a research report issued to clients and investors on Monday. They presently have a $141.00 target price on the biopharmaceutical company’s stock. BMO Capital Markets’ price target would suggest a potential upside of 43.15% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the company. Jefferies Group reissued a “buy” rating and set a $138.00 price target on shares of Celgene Corp. in a research report on Sunday, July 10th. BTIG Research reissued a “buy” rating and set a $138.00 price target on shares of Celgene Corp. in a research report on Sunday, August 21st. Vetr downgraded Celgene Corp. from a “buy” rating to a “hold” rating and set a $106.06 price target on the stock. in a research report on Wednesday, July 6th. Morgan Stanley reissued an “equal weight” rating and set a $120.00 price target on shares of Celgene Corp. in a research report on Monday, September 12th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $145.00 price target on shares of Celgene Corp. in a research report on Sunday, October 2nd. Three equities research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $136.46.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) traded up 1.386% during trading on Monday, hitting $99.865. The company had a trading volume of 2,890,299 shares. Celgene Corp. has a one year low of $93.05 and a one year high of $128.39. The company has a market capitalization of $77.41 billion, a price-to-earnings ratio of 42.208 and a beta of 1.49. The stock has a 50-day moving average of $105.76 and a 200 day moving average of $105.48.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.05. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. The firm’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.23 earnings per share. Equities analysts forecast that Celgene Corp. will post $5.71 EPS for the current fiscal year.

In other Celgene Corp. news, Director James J. Loughlin sold 27,500 shares of Celgene Corp. stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $114.10, for a total transaction of $3,137,750.00. Following the transaction, the director now owns 42,919 shares of the company’s stock, valued at approximately $4,897,057.90. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Robert J. Hugin sold 100,000 shares of Celgene Corp. stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $110.00, for a total transaction of $11,000,000.00. Following the transaction, the insider now directly owns 1,022,201 shares in the company, valued at approximately $112,442,110. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. Park National Corp OH boosted its position in Celgene Corp. by 0.4% in the third quarter. Park National Corp OH now owns 3,158 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 12 shares in the last quarter. Ropes Wealth Advisors LLC boosted its position in Celgene Corp. by 0.9% in the first quarter. Ropes Wealth Advisors LLC now owns 1,477 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 13 shares in the last quarter. Kings Point Capital Management boosted its position in Celgene Corp. by 1.7% in the first quarter. Kings Point Capital Management now owns 1,316 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 22 shares in the last quarter. Jolley Asset Management LLC boosted its position in Celgene Corp. by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares in the last quarter. Finally, Gradient Investments LLC boosted its position in Celgene Corp. by 0.9% in the third quarter. Gradient Investments LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 29 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.